Abrdn Life Sciences Investors (HQL) Stock Price, News & Analysis

Company Overview

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Key Stats

• Today's Range: $12.84 to $13.03
• 50-Day Range: $10.81 to $13.45
• 52-Week Range: $10.55 to $15.90
• Volume: 77,532 shs
• Average Volume: 101,868 shs
• Market Capitalization: $375.34 million
• P/E Ratio: N/A
• Dividend Yield: 11.31%
• Price Target: N/A
• Consensus Rating: N/A

HQL Stock Analysis - Frequently Asked Questions

How have HQL shares performed this year?

Abrdn Life Sciences Investors' stock was trading at $13.12 at the start of the year. Since then, HQL shares have decreased by 0.9% and is now trading at $13.00.
View the best growth stocks for 2025 here.

Who are Abrdn Life Sciences Investors' major shareholders?

Top institutional investors of Abrdn Life Sciences Investors include Penserra Capital Management LLC (2.59%), Flagship Harbor Advisors LLC (1.18%), Allspring Global Investments Holdings LLC (0.67%) and Absolute Investment Advisers LLC (0.67%). Insiders that own company stock include Saba Capital Management, LP, Daniel R Omstead, Kathleen Goetz, Todd Reit and Rose Dimartino.
View institutional ownership trends.

How do I buy shares of Abrdn Life Sciences Investors?

Shares of HQL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Abrdn Life Sciences Investors own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abrdn Life Sciences Investors investors own include Rithm Capital (RITM), DoubleLine Income Solutions Fund (DSL), Medical Properties Trust (MPW), Verizon Communications (VZ), International Business Machines (IBM), Eaton Vance Tax-Managed Global Diversified Equity Income Fund (EXG) and Energy Transfer (ET).

Company Calendar

• Record date for 3/31 Dividend: 2/21/2025
• Ex-Dividend for 3/31 Dividend: 2/21/2025
• Dividend Payable: 3/31/2025
• Today: 5/03/2025
• Next Earnings (Estimated): 6/09/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Finance
• Industry: Investment offices, not elsewhere classified
• Sub-Industry: Financial Services
• Current Symbol: NYSE:HQL
• CIK: 884121
• Web: www.teklacap.com
• Phone: (617) 772-8500
• Fax: 617-772-8577
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $86.69 million
• Price / Sales: 4.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 28,872,000
• Free Float: 24,599,000
• Market Cap: $375.34 million
• Optionable: Not Optionable
• Beta: 0.76